SCHEMBL22853345

SCHEMBL22853345

CCc1cc(F)ccc1Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 1/20 0.51
GAA P10253 1/20 0.49
FABP3 P05413 2/20 0.49
FABP4 P15090 2/20 0.49
MPO P05164 1/20 0.47
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KCNH2 Q12809 1/20 0.44
MRGPRX1 Q96LB2 1/20 0.44
GRIK1 P39086 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853097 0.90 FABP3 (0.51) KDM4EGAAFABP3FABP4MPO
SCHEMBL30294242 0.90 FABP3 (0.51) KDM4EGAAFABP3FABP4MPO
SCHEMBL22853333 0.87 ALDH1A1 (0.46) KDM4EGAAMEN1KMT2AALDH1A1
SCHEMBL22853159 0.84 FABP3 (0.47) GAAFABP3FABP4MPOALDH1A1
SCHEMBL30294345 0.84 FABP3 (0.47) GAAFABP3FABP4MPOALDH1A1
SCHEMBL30294397 0.83 KDM4E (0.54) KDM4EHSD17B10FABP3FABP4MPO
SCHEMBL22852993 0.83 KDM4E (0.54) KDM4EHSD17B10FABP3FABP4MPO
SCHEMBL30294352 0.83 KDM4E (0.54) KDM4EHSD17B10GAAFABP3FABP4
SCHEMBL22852839 0.83 KDM4E (0.54) KDM4EHSD17B10GAAFABP3FABP4
SCHEMBL22853109 0.82 MRGPRX1 (0.56) KDM4EHSD17B10GAAFABP3FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B KDM4E 3392/4885HSD17B10 4145/4885GAA 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.